Novartis spent $51 billion in Alcon to add $1.9 billion sales in the current 2011 quarter, J&J managed to improve earnings to close to $3.77 billion excluding litigation costs to $1.35 per share while counterbalancing its medical device revenues of $2 billion with a pitch for Synthes. Core Earnings at Novartis were up to $1.41 per share despite sales lowerby $1.1 billion in anti-flu sales and more expected in reducing Diovan
Constant currency sales at Novartis topped $14 billion and J&J sales topped $16.1 billion. International sales were mostly responsible for the J&J recovery at 7% up tick
Image via Wikipedia
Write text here...
No comments:
Post a Comment